Assessment of Simplified Methods for Quantification of 18 F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer
F-fluorodihydrotestosterone ( F-FDHT) PET/CT potentially provides a noninvasive method for assessment of androgen receptor expression in patients with metastatic castration-resistant prostate cancer (mCRPC). The objective of this study was to assess simplified methods for quantifying F-FDHT uptake i...
Gespeichert in:
| Veröffentlicht in: | Journal of Nuclear Medicine 2019-09, Vol.60 (9), p.1221-1227 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1227 |
|---|---|
| container_issue | 9 |
| container_start_page | 1221 |
| container_title | Journal of Nuclear Medicine |
| container_volume | 60 |
| creator | Kramer, Gerbrand M Yaqub, Maqsood Vargas, Herbert A Schuit, Robert C Windhorst, Albert D van den Eertwegh, Alfonsus J M van der Veldt, Astrid A M Bergman, Andries M Burnazi, Eva M Lewis, Jason S Chua, Sua Staton, Kevin D Beattie, Brad J Humm, John L Davis, Ian D Weickhardt, Andrew J Scott, Andrew M Morris, Michael J Hoekstra, Otto S Lammertsma, Adriaan A |
| description | F-fluorodihydrotestosterone (
F-FDHT) PET/CT potentially provides a noninvasive method for assessment of androgen receptor expression in patients with metastatic castration-resistant prostate cancer (mCRPC). The objective of this study was to assess simplified methods for quantifying
F-FDHT uptake in mCRPC patients and to assess effects of tumor perfusion on these
F-FDHT uptake metrics.
Seventeen mCRPC patients were included in this prospective observational multicenter study. Test and retest 30-min dynamic
F-FDHT PET/CT scans with venous blood sampling were performed in 14 patients. In addition, arterial blood sampling and dynamic
O-H
O scans were obtained in a subset of 6 patients. Several simplified methods were assessed: Patlak plots; SUV normalized to body weight (SUV
), lean body mass (SUV
), whole blood (SUV
), parent plasma activity concentration (SUV
), area under the parent plasma curve (SUV
), and area under the whole-blood input curve (SUV
); and SUV
corrected for sex hormone-binding globulin levels (SUV
). Results were correlated with parameters derived from full pharmacokinetic
F-FDHT and
O-H
O. Finally, the repeatability of individual quantitative uptake metrics was assessed.
Eighty-seven
F-FDHT-avid lesions were evaluated.
F-FDHT uptake was best described by an irreversible 2-tissue-compartment model. Replacing the continuous metabolite-corrected arterial plasma input function with an image-derived input function in combination with venous sample data provided similar
results (
= 0.98). Patlak
and SUV
showed an excellent correlation (
> 0.9). SUV
showed a moderate correlation to
(
= 0.70, presumably due to fast
F-FDHT metabolism. When calculating SUV
, correlation to
improved (
= 0.88). The repeatability of full kinetic modeling parameters was inferior to that of simplified methods (repeatability coefficients > 36% vs. < 28%, respectively).
F-FDHT uptake showed minimal blood flow dependency.
F-FDHT kinetics in mCRPC patients are best described by an irreversible 2-tissue-compartment model with blood volume parameter. SUV
showed a near-perfect correlation with the irreversible 2-tissue-compartment model analysis and can be used for accurate quantification of
F-FDHT uptake in whole-body PET/CT scans. In addition, SUV
could potentially be used as an even simpler method to quantify
F-FDHT uptake when less complex scanning protocols and accuracy are required. |
| doi_str_mv | 10.2967/jnumed.118.220111 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2967_jnumed_118_220111</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30850488</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1138-21f211c86ac9de1c94941f36a0bd177f2dc4f5ec4bb32fc13915ec1b44770a483</originalsourceid><addsrcrecordid>eNo1kEtOwzAURS0EoqWwACbIG0jx8ydxhlWhFKmIAu04chxbdWk-ilMhdsCycQgd2b7X5z3pIHQLZErTOLnfV8fSFFMAOaWUAMAZGoNgIhJxnJyjMYEYIiGIGKEr7_eEkFhKeYlGjEhBuJRj9DPz3nhfmqrDtcUfrmwOzjpT4BfT7erCY1u3-O2oqi7EWnWurvqPIPEiWjwsN3jbdOrTYFfhdWjDHI-_XLfreeW7EGk8D5f2D43ejXchDdvWbd3XJrSVNu01urDq4M3N_zlB28XjZr6MVq9Pz_PZKtIATEYULAXQMlY6LQzolKccLIsVyQtIEksLza0wmuc5o1YDSyG8IOc8SYjikk0QDHN12O9bY7OmdaVqvzMgWW81G6xmwWo2WA3M3cA0x7yvTsRJI_sFjPR2RA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Assessment of Simplified Methods for Quantification of 18 F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Kramer, Gerbrand M ; Yaqub, Maqsood ; Vargas, Herbert A ; Schuit, Robert C ; Windhorst, Albert D ; van den Eertwegh, Alfonsus J M ; van der Veldt, Astrid A M ; Bergman, Andries M ; Burnazi, Eva M ; Lewis, Jason S ; Chua, Sua ; Staton, Kevin D ; Beattie, Brad J ; Humm, John L ; Davis, Ian D ; Weickhardt, Andrew J ; Scott, Andrew M ; Morris, Michael J ; Hoekstra, Otto S ; Lammertsma, Adriaan A</creator><creatorcontrib>Kramer, Gerbrand M ; Yaqub, Maqsood ; Vargas, Herbert A ; Schuit, Robert C ; Windhorst, Albert D ; van den Eertwegh, Alfonsus J M ; van der Veldt, Astrid A M ; Bergman, Andries M ; Burnazi, Eva M ; Lewis, Jason S ; Chua, Sua ; Staton, Kevin D ; Beattie, Brad J ; Humm, John L ; Davis, Ian D ; Weickhardt, Andrew J ; Scott, Andrew M ; Morris, Michael J ; Hoekstra, Otto S ; Lammertsma, Adriaan A</creatorcontrib><description>F-fluorodihydrotestosterone (
F-FDHT) PET/CT potentially provides a noninvasive method for assessment of androgen receptor expression in patients with metastatic castration-resistant prostate cancer (mCRPC). The objective of this study was to assess simplified methods for quantifying
F-FDHT uptake in mCRPC patients and to assess effects of tumor perfusion on these
F-FDHT uptake metrics.
Seventeen mCRPC patients were included in this prospective observational multicenter study. Test and retest 30-min dynamic
F-FDHT PET/CT scans with venous blood sampling were performed in 14 patients. In addition, arterial blood sampling and dynamic
O-H
O scans were obtained in a subset of 6 patients. Several simplified methods were assessed: Patlak plots; SUV normalized to body weight (SUV
), lean body mass (SUV
), whole blood (SUV
), parent plasma activity concentration (SUV
), area under the parent plasma curve (SUV
), and area under the whole-blood input curve (SUV
); and SUV
corrected for sex hormone-binding globulin levels (SUV
). Results were correlated with parameters derived from full pharmacokinetic
F-FDHT and
O-H
O. Finally, the repeatability of individual quantitative uptake metrics was assessed.
Eighty-seven
F-FDHT-avid lesions were evaluated.
F-FDHT uptake was best described by an irreversible 2-tissue-compartment model. Replacing the continuous metabolite-corrected arterial plasma input function with an image-derived input function in combination with venous sample data provided similar
results (
= 0.98). Patlak
and SUV
showed an excellent correlation (
> 0.9). SUV
showed a moderate correlation to
(
= 0.70, presumably due to fast
F-FDHT metabolism. When calculating SUV
, correlation to
improved (
= 0.88). The repeatability of full kinetic modeling parameters was inferior to that of simplified methods (repeatability coefficients > 36% vs. < 28%, respectively).
F-FDHT uptake showed minimal blood flow dependency.
F-FDHT kinetics in mCRPC patients are best described by an irreversible 2-tissue-compartment model with blood volume parameter. SUV
showed a near-perfect correlation with the irreversible 2-tissue-compartment model analysis and can be used for accurate quantification of
F-FDHT uptake in whole-body PET/CT scans. In addition, SUV
could potentially be used as an even simpler method to quantify
F-FDHT uptake when less complex scanning protocols and accuracy are required.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>EISSN: 2159-662X</identifier><identifier>DOI: 10.2967/jnumed.118.220111</identifier><identifier>PMID: 30850488</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Aged, 80 and over ; Body Weight ; Dihydrotestosterone - analogs & derivatives ; Dihydrotestosterone - pharmacokinetics ; Fluorine Radioisotopes - pharmacokinetics ; Humans ; Image Processing, Computer-Assisted ; Kinetics ; Male ; Middle Aged ; Neoplasm Metastasis ; Positron Emission Tomography Computed Tomography ; Prospective Studies ; Prostatic Neoplasms, Castration-Resistant - diagnostic imaging ; Radiopharmaceuticals - pharmacokinetics ; Reproducibility of Results</subject><ispartof>Journal of Nuclear Medicine, 2019-09, Vol.60 (9), p.1221-1227</ispartof><rights>2019 by the Society of Nuclear Medicine and Molecular Imaging.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1138-21f211c86ac9de1c94941f36a0bd177f2dc4f5ec4bb32fc13915ec1b44770a483</citedby><cites>FETCH-LOGICAL-c1138-21f211c86ac9de1c94941f36a0bd177f2dc4f5ec4bb32fc13915ec1b44770a483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30850488$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kramer, Gerbrand M</creatorcontrib><creatorcontrib>Yaqub, Maqsood</creatorcontrib><creatorcontrib>Vargas, Herbert A</creatorcontrib><creatorcontrib>Schuit, Robert C</creatorcontrib><creatorcontrib>Windhorst, Albert D</creatorcontrib><creatorcontrib>van den Eertwegh, Alfonsus J M</creatorcontrib><creatorcontrib>van der Veldt, Astrid A M</creatorcontrib><creatorcontrib>Bergman, Andries M</creatorcontrib><creatorcontrib>Burnazi, Eva M</creatorcontrib><creatorcontrib>Lewis, Jason S</creatorcontrib><creatorcontrib>Chua, Sua</creatorcontrib><creatorcontrib>Staton, Kevin D</creatorcontrib><creatorcontrib>Beattie, Brad J</creatorcontrib><creatorcontrib>Humm, John L</creatorcontrib><creatorcontrib>Davis, Ian D</creatorcontrib><creatorcontrib>Weickhardt, Andrew J</creatorcontrib><creatorcontrib>Scott, Andrew M</creatorcontrib><creatorcontrib>Morris, Michael J</creatorcontrib><creatorcontrib>Hoekstra, Otto S</creatorcontrib><creatorcontrib>Lammertsma, Adriaan A</creatorcontrib><title>Assessment of Simplified Methods for Quantification of 18 F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer</title><title>Journal of Nuclear Medicine</title><addtitle>J Nucl Med</addtitle><description>F-fluorodihydrotestosterone (
F-FDHT) PET/CT potentially provides a noninvasive method for assessment of androgen receptor expression in patients with metastatic castration-resistant prostate cancer (mCRPC). The objective of this study was to assess simplified methods for quantifying
F-FDHT uptake in mCRPC patients and to assess effects of tumor perfusion on these
F-FDHT uptake metrics.
Seventeen mCRPC patients were included in this prospective observational multicenter study. Test and retest 30-min dynamic
F-FDHT PET/CT scans with venous blood sampling were performed in 14 patients. In addition, arterial blood sampling and dynamic
O-H
O scans were obtained in a subset of 6 patients. Several simplified methods were assessed: Patlak plots; SUV normalized to body weight (SUV
), lean body mass (SUV
), whole blood (SUV
), parent plasma activity concentration (SUV
), area under the parent plasma curve (SUV
), and area under the whole-blood input curve (SUV
); and SUV
corrected for sex hormone-binding globulin levels (SUV
). Results were correlated with parameters derived from full pharmacokinetic
F-FDHT and
O-H
O. Finally, the repeatability of individual quantitative uptake metrics was assessed.
Eighty-seven
F-FDHT-avid lesions were evaluated.
F-FDHT uptake was best described by an irreversible 2-tissue-compartment model. Replacing the continuous metabolite-corrected arterial plasma input function with an image-derived input function in combination with venous sample data provided similar
results (
= 0.98). Patlak
and SUV
showed an excellent correlation (
> 0.9). SUV
showed a moderate correlation to
(
= 0.70, presumably due to fast
F-FDHT metabolism. When calculating SUV
, correlation to
improved (
= 0.88). The repeatability of full kinetic modeling parameters was inferior to that of simplified methods (repeatability coefficients > 36% vs. < 28%, respectively).
F-FDHT uptake showed minimal blood flow dependency.
F-FDHT kinetics in mCRPC patients are best described by an irreversible 2-tissue-compartment model with blood volume parameter. SUV
showed a near-perfect correlation with the irreversible 2-tissue-compartment model analysis and can be used for accurate quantification of
F-FDHT uptake in whole-body PET/CT scans. In addition, SUV
could potentially be used as an even simpler method to quantify
F-FDHT uptake when less complex scanning protocols and accuracy are required.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Body Weight</subject><subject>Dihydrotestosterone - analogs & derivatives</subject><subject>Dihydrotestosterone - pharmacokinetics</subject><subject>Fluorine Radioisotopes - pharmacokinetics</subject><subject>Humans</subject><subject>Image Processing, Computer-Assisted</subject><subject>Kinetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Prospective Studies</subject><subject>Prostatic Neoplasms, Castration-Resistant - diagnostic imaging</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Reproducibility of Results</subject><issn>0161-5505</issn><issn>1535-5667</issn><issn>2159-662X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtOwzAURS0EoqWwACbIG0jx8ydxhlWhFKmIAu04chxbdWk-ilMhdsCycQgd2b7X5z3pIHQLZErTOLnfV8fSFFMAOaWUAMAZGoNgIhJxnJyjMYEYIiGIGKEr7_eEkFhKeYlGjEhBuJRj9DPz3nhfmqrDtcUfrmwOzjpT4BfT7erCY1u3-O2oqi7EWnWurvqPIPEiWjwsN3jbdOrTYFfhdWjDHI-_XLfreeW7EGk8D5f2D43ejXchDdvWbd3XJrSVNu01urDq4M3N_zlB28XjZr6MVq9Pz_PZKtIATEYULAXQMlY6LQzolKccLIsVyQtIEksLza0wmuc5o1YDSyG8IOc8SYjikk0QDHN12O9bY7OmdaVqvzMgWW81G6xmwWo2WA3M3cA0x7yvTsRJI_sFjPR2RA</recordid><startdate>201909</startdate><enddate>201909</enddate><creator>Kramer, Gerbrand M</creator><creator>Yaqub, Maqsood</creator><creator>Vargas, Herbert A</creator><creator>Schuit, Robert C</creator><creator>Windhorst, Albert D</creator><creator>van den Eertwegh, Alfonsus J M</creator><creator>van der Veldt, Astrid A M</creator><creator>Bergman, Andries M</creator><creator>Burnazi, Eva M</creator><creator>Lewis, Jason S</creator><creator>Chua, Sua</creator><creator>Staton, Kevin D</creator><creator>Beattie, Brad J</creator><creator>Humm, John L</creator><creator>Davis, Ian D</creator><creator>Weickhardt, Andrew J</creator><creator>Scott, Andrew M</creator><creator>Morris, Michael J</creator><creator>Hoekstra, Otto S</creator><creator>Lammertsma, Adriaan A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201909</creationdate><title>Assessment of Simplified Methods for Quantification of 18 F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer</title><author>Kramer, Gerbrand M ; Yaqub, Maqsood ; Vargas, Herbert A ; Schuit, Robert C ; Windhorst, Albert D ; van den Eertwegh, Alfonsus J M ; van der Veldt, Astrid A M ; Bergman, Andries M ; Burnazi, Eva M ; Lewis, Jason S ; Chua, Sua ; Staton, Kevin D ; Beattie, Brad J ; Humm, John L ; Davis, Ian D ; Weickhardt, Andrew J ; Scott, Andrew M ; Morris, Michael J ; Hoekstra, Otto S ; Lammertsma, Adriaan A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1138-21f211c86ac9de1c94941f36a0bd177f2dc4f5ec4bb32fc13915ec1b44770a483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Body Weight</topic><topic>Dihydrotestosterone - analogs & derivatives</topic><topic>Dihydrotestosterone - pharmacokinetics</topic><topic>Fluorine Radioisotopes - pharmacokinetics</topic><topic>Humans</topic><topic>Image Processing, Computer-Assisted</topic><topic>Kinetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Prospective Studies</topic><topic>Prostatic Neoplasms, Castration-Resistant - diagnostic imaging</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Reproducibility of Results</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kramer, Gerbrand M</creatorcontrib><creatorcontrib>Yaqub, Maqsood</creatorcontrib><creatorcontrib>Vargas, Herbert A</creatorcontrib><creatorcontrib>Schuit, Robert C</creatorcontrib><creatorcontrib>Windhorst, Albert D</creatorcontrib><creatorcontrib>van den Eertwegh, Alfonsus J M</creatorcontrib><creatorcontrib>van der Veldt, Astrid A M</creatorcontrib><creatorcontrib>Bergman, Andries M</creatorcontrib><creatorcontrib>Burnazi, Eva M</creatorcontrib><creatorcontrib>Lewis, Jason S</creatorcontrib><creatorcontrib>Chua, Sua</creatorcontrib><creatorcontrib>Staton, Kevin D</creatorcontrib><creatorcontrib>Beattie, Brad J</creatorcontrib><creatorcontrib>Humm, John L</creatorcontrib><creatorcontrib>Davis, Ian D</creatorcontrib><creatorcontrib>Weickhardt, Andrew J</creatorcontrib><creatorcontrib>Scott, Andrew M</creatorcontrib><creatorcontrib>Morris, Michael J</creatorcontrib><creatorcontrib>Hoekstra, Otto S</creatorcontrib><creatorcontrib>Lammertsma, Adriaan A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of Nuclear Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kramer, Gerbrand M</au><au>Yaqub, Maqsood</au><au>Vargas, Herbert A</au><au>Schuit, Robert C</au><au>Windhorst, Albert D</au><au>van den Eertwegh, Alfonsus J M</au><au>van der Veldt, Astrid A M</au><au>Bergman, Andries M</au><au>Burnazi, Eva M</au><au>Lewis, Jason S</au><au>Chua, Sua</au><au>Staton, Kevin D</au><au>Beattie, Brad J</au><au>Humm, John L</au><au>Davis, Ian D</au><au>Weickhardt, Andrew J</au><au>Scott, Andrew M</au><au>Morris, Michael J</au><au>Hoekstra, Otto S</au><au>Lammertsma, Adriaan A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of Simplified Methods for Quantification of 18 F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer</atitle><jtitle>Journal of Nuclear Medicine</jtitle><addtitle>J Nucl Med</addtitle><date>2019-09</date><risdate>2019</risdate><volume>60</volume><issue>9</issue><spage>1221</spage><epage>1227</epage><pages>1221-1227</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><eissn>2159-662X</eissn><abstract>F-fluorodihydrotestosterone (
F-FDHT) PET/CT potentially provides a noninvasive method for assessment of androgen receptor expression in patients with metastatic castration-resistant prostate cancer (mCRPC). The objective of this study was to assess simplified methods for quantifying
F-FDHT uptake in mCRPC patients and to assess effects of tumor perfusion on these
F-FDHT uptake metrics.
Seventeen mCRPC patients were included in this prospective observational multicenter study. Test and retest 30-min dynamic
F-FDHT PET/CT scans with venous blood sampling were performed in 14 patients. In addition, arterial blood sampling and dynamic
O-H
O scans were obtained in a subset of 6 patients. Several simplified methods were assessed: Patlak plots; SUV normalized to body weight (SUV
), lean body mass (SUV
), whole blood (SUV
), parent plasma activity concentration (SUV
), area under the parent plasma curve (SUV
), and area under the whole-blood input curve (SUV
); and SUV
corrected for sex hormone-binding globulin levels (SUV
). Results were correlated with parameters derived from full pharmacokinetic
F-FDHT and
O-H
O. Finally, the repeatability of individual quantitative uptake metrics was assessed.
Eighty-seven
F-FDHT-avid lesions were evaluated.
F-FDHT uptake was best described by an irreversible 2-tissue-compartment model. Replacing the continuous metabolite-corrected arterial plasma input function with an image-derived input function in combination with venous sample data provided similar
results (
= 0.98). Patlak
and SUV
showed an excellent correlation (
> 0.9). SUV
showed a moderate correlation to
(
= 0.70, presumably due to fast
F-FDHT metabolism. When calculating SUV
, correlation to
improved (
= 0.88). The repeatability of full kinetic modeling parameters was inferior to that of simplified methods (repeatability coefficients > 36% vs. < 28%, respectively).
F-FDHT uptake showed minimal blood flow dependency.
F-FDHT kinetics in mCRPC patients are best described by an irreversible 2-tissue-compartment model with blood volume parameter. SUV
showed a near-perfect correlation with the irreversible 2-tissue-compartment model analysis and can be used for accurate quantification of
F-FDHT uptake in whole-body PET/CT scans. In addition, SUV
could potentially be used as an even simpler method to quantify
F-FDHT uptake when less complex scanning protocols and accuracy are required.</abstract><cop>United States</cop><pmid>30850488</pmid><doi>10.2967/jnumed.118.220111</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | Journal of Nuclear Medicine, 2019-09, Vol.60 (9), p.1221-1227 |
| issn | 0161-5505 1535-5667 2159-662X |
| language | eng |
| recordid | cdi_crossref_primary_10_2967_jnumed_118_220111 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Body Weight Dihydrotestosterone - analogs & derivatives Dihydrotestosterone - pharmacokinetics Fluorine Radioisotopes - pharmacokinetics Humans Image Processing, Computer-Assisted Kinetics Male Middle Aged Neoplasm Metastasis Positron Emission Tomography Computed Tomography Prospective Studies Prostatic Neoplasms, Castration-Resistant - diagnostic imaging Radiopharmaceuticals - pharmacokinetics Reproducibility of Results |
| title | Assessment of Simplified Methods for Quantification of 18 F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T22%3A43%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20Simplified%20Methods%20for%20Quantification%20of%2018%20F-FDHT%20Uptake%20in%20Patients%20with%20Metastatic%20Castration-Resistant%20Prostate%20Cancer&rft.jtitle=Journal%20of%20Nuclear%20Medicine&rft.au=Kramer,%20Gerbrand%20M&rft.date=2019-09&rft.volume=60&rft.issue=9&rft.spage=1221&rft.epage=1227&rft.pages=1221-1227&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/10.2967/jnumed.118.220111&rft_dat=%3Cpubmed_cross%3E30850488%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30850488&rfr_iscdi=true |